Clinical outcomes of afatinib versus osimertinib in patients with non-small cell lung cancer with uncommon EGFR mutations: a pooled analysis
C Wang, K Zhao, S Hu, W Dong, Y Gong, C Xie - The Oncologist, 2023 - academic.oup.com
Background The purpose of this analysis was to investigate the effectiveness of afatinib
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …
[HTML][HTML] EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors
H Xu, G Yang, R Liu, Y Yang, W Li, J Li… - Frontiers in …, 2022 - frontiersin.org
Background: Approximately 10% of patients with non-small cell lung cancer (NSCLC) harbor
uncommon epidermal growth factor receptor (EGFR) alterations. This study aims to …
uncommon epidermal growth factor receptor (EGFR) alterations. This study aims to …
[HTML][HTML] Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal …
S Hu, C Wang, C Wang, K Zhao, Z Wang… - Frontiers in …, 2022 - frontiersin.org
Background: In this pooled analysis, the aim was to investigate the clinicopathological
characteristics of patients with uncommon epidermal growth factor receptor (EGFR)(ucm …
characteristics of patients with uncommon epidermal growth factor receptor (EGFR)(ucm …
[HTML][HTML] 阿美替尼联合贝伐珠单抗治疗晚期NSCLC 伴原发EGFR T790M 突变： 3 例病案报道及文献复习
Y Xue, M Fanlu, D ZHONG - Chinese Journal of Lung Cancer, 2023 - ncbi.nlm.nih.gov
随着检测技术的发展， 非小细胞肺癌患者（ non-small cell lung cancer, NSCLC）
伴原发表皮生长因子受体（ epidermal growth factor receptor, EGFR） T790M …
伴原发表皮生长因子受体（ epidermal growth factor receptor, EGFR） T790M …
Treatment Outcomes in Patients with Atypical EGFR-positive Non-small Cell Lung Cancer in Nagano Prefecture, Japan
T Agatsuma, S Kanda, R Yamamoto, Y Ono… - THE SHINSHU …, 2022 - jstage.jst.go.jp
Background: This study was performed to evaluate clinical practices in patients with atypical
epidermal growth factor receptor (EGFR)-positive inoperable non-small cell lung cancer …
epidermal growth factor receptor (EGFR)-positive inoperable non-small cell lung cancer …
Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature …
Y Xue, M Fanlu, D Zhong - Chinese Journal of Lung Cancer, 2023 - search.ebscohost.com
With the development of sequencing technology, the detection rate of non-small cell lung
cancer (NSCLC) with primary epidermal growth factor receptor (EGFR) T790M mutation is …
cancer (NSCLC) with primary epidermal growth factor receptor (EGFR) T790M mutation is …